Matrix sells its entire stake in Concord to Promoter and existing investors

Concord Biotech Limited is an R&D based Biotechnology company, having focus on the fermentation, semi-synthetic and synthesis based products. Since its inception in 2000, Concord has recorded an excellent growth through diversification and process improvements. Having state-of-the-art US FDA approved facility; Concord is a professionally managed globally recognised supplier of fermentation based API’s and enzyme & offers services in biotechnology area like strain improvement & contract fermentation/ manufacturing.

The existing portfolio of products includes API’s in the immunosuppressant, antibiotic, hypolipemic segments and enzymes. However, with the expertise in the field of biotechnology and chemistry, the R&D team at Concord is working towards adding new products to the product basket.

Vision Mission
Create products through Biotechnology route and service offerings that enrich the lives of people by continually building on our expertise in Biotechnology.
We strive to be a global power in the field of Biotechnology based products through research and development to create sustainable earnings growth and to establish long term business success. We continue to reinforce our commitment to safety, health and environment. We endeavor for an environment where creativity and effectiveness are encouraged with the technologies for the niche market
Company News June 200930% increase in the total fermentation capacity by addition of another fermentation block. June 2009With the addition of two new products, Cyclosporine & Sirolimus, Concord is one of the few companies in the world supplying the entire immunosuppressant range of products. May 2009 Concord is one of the front runners in the US market for Mycophenolate Mofetil with its first successful day 1 launch with its ANDA partners. May 2009Concord receives GMP certification by Australian TGA (Therapeutic Goods Administration) for couple of its products. Read more...